Biotechnology News and Research RSS Feed - Biotechnology News and Research

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with an intense, red, itchy rash on their outer genital organs may be at increased risk of developing urinary tract infections (UTIs), according to new research from Wake Forest Baptist Medical Center. The treatment may be as simple as better hygiene and avoiding potential irritants such as bubble baths and swimming pools. [More]
Blockbuster Fifty Shades linked with greater risk of harmful health behaviors in women

Blockbuster Fifty Shades linked with greater risk of harmful health behaviors in women

Popular fiction that normalizes and glamorizes violence against women, such as the blockbuster Fifty Shades series, may be associated with a greater risk of potentially harmful health behaviors and risks. [More]

Dr. John S. Sampalis nominated as finalist in the 2014 EY Entrepreneur Of The Year award

Dr. John S. Sampalis is founder and CEO of JSS Medical Research and one of the world's leading clinical epidemiologists. Dr. Sampalis is nominated as a finalist in this year's 2014 EY Entrepreneur Of The Year in the Québec Health Sciences category. [More]
Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm. [More]
Research shows long non-coding RNAs regulate circadian clocks

Research shows long non-coding RNAs regulate circadian clocks

Researchers at UT Southwestern Medical Center have found a new way that internal body clocks are regulated by a type of molecule known as long non-coding RNA. [More]
Cellular Research announces start of early access program for Precise assays

Cellular Research announces start of early access program for Precise assays

Cellular Research announced today the start of an early access program for its Precise assays and is currently making the product available to 10 sites. [More]
Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. [More]

Global life science reagents market to grow at 10.8% CAGR from 2013 to 2019

According to a new market report published by Transparency Market Research "Life Science Reagents Market(Products- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and Others; End Users- Commercial and Contract Manufacturers, Research and Academic Institutions, Clinical Laboratories, and Forensic Laboratories)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", the global life science reagents market was valued at USD 12.44 billionin 2012 and is expected to grow at a CAGR of 10.8% from 2013 to 2019, to reach an estimated value of USD 25.73 billion in 2019. [More]
Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir plans to seek approval, launch novel drug for treatment of Ebola infection

Globavir Biosciences, Inc., a biotechnology company developing therapeutics to treat infectious diseases, has announced intentions to develop its lead drug candidate, GBV006, for the treatment of the current Ebola Virus outbreak in West Africa. Globavir will seek approval for the use of GBV006, a combination of Food and Drug Administration approved drugs, through an established compassionate use regulatory pathway. [More]
ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A. [More]

HUYA Bioscience International announces strategic partnership with CZCBD

HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD). [More]

China Pharma Holdings' Q2 2014 revenue decreases by 24% to $6.1 million

China Pharma Holdings, Inc., an NYSE MKT listed corporation with its fully-integrated specialty pharmaceuticals subsidiary based in China, today announced its financial results for the three months ended June 30, 2014. [More]
Dyadic's net product related revenue for Q2 2014 increases 28% to $4.9 million

Dyadic's net product related revenue for Q2 2014 increases 28% to $4.9 million

Dyadic International, Inc., a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the second quarter ended June 30, 2014. [More]
University of California launches 14 commercial startups in a year

University of California launches 14 commercial startups in a year

The University of California, Davis, launched 14 commercial startups during the past year to June 30 - the largest number of new ventures based on UC Davis technology to be started in a single year. [More]
Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections could benefit from improved treatment

Babies suffering from life-threatening bacterial infections such as sepsis could benefit from improved treatment, thanks to a ground-breaking study. [More]
Health institutions tackle high rate of preterm birth

Health institutions tackle high rate of preterm birth

An estimated 15 million babies are born preterm every year and more than one million die within the first 30 days after birth. [More]
Novogen declares shareholder meeting results

Novogen declares shareholder meeting results

Australia-US biotechnology company, Novogen Ltd., an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia. [More]
Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). [More]
Heart failure is major public health burden in many LMICs

Heart failure is major public health burden in many LMICs

Heart failure is a major public health burden in many low- and middle-income countries (LMICs), with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine. [More]